Table 2.
Subgroup analysis for the risk of T2DM in patients with schizophrenia.
| Subgroup | Included studies | OR (95% CI) | Heterogeneity | |
|---|---|---|---|---|
| I2 (%) | P-values | |||
| Gender | ||||
| Male | 11 | 1.68(1.39-2.04) | 91.3% | 0.000 |
| Female | 9 | 2.12(1.70-2.64) | 90.7% | 0.000 |
| WHO region | ||||
| WPRO | 9 | 1.72(1.32-2.23) | 95.2 | 0.000 |
| EURO | 11 | 2.73(2.23-3.35) | 97.5 | 0.000 |
| AMRO | 9 | 1.82(1.40-2.37) | 99.1 | 0.000 |
| Study type | ||||
| Cohort study | 14 | 2.11(1.83-2.67) | 98.4% | 0.000 |
| Cross-sectional study | 15 | 2.04(1.47-2.83) | 99.1% | 0.000 |
| Case-control study | 2 | 2.58(1.34-4.97) | 72.6% | 0.056 |
| Follow-up years | ||||
| <10 | 7 | 1.68(1.30-2.19) | 95.4% | 0.000 |
| 10-20 | 6 | 2.26(1.76-2.90) | 98.6% | 0.000 |
| >20 | 3 | 3.17(1.24-8.11) | 99.4% | 0.000 |